Skip to main content

Clinical Trials Using Dexamethasone

Review the clinical trials studying dexamethasone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 141

Post-Operative Dosing of Dexamethasone in Patients with Brain Tumors after a Craniotomy, PODS trial
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients with Extramedullary Disease
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
Status: Active
Location: University of California San Francisco, San Francisco, California
Minimal Residual Disease Response after Completing Therapeutic Drug Regimen with Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma, MILESTONE Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Tertiary and Community Care Models for the Administration of Hepatic Artery Infusion Chemotherapy in Patients with Unresectable or Resectable Colorectal Liver Metastases and Unresectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Carboplatin, Paclitaxel, and Ramucirumab for the Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Emapalumab for the Prevention of CAR-T Cell Associated Cytokine Release Syndrome in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active
Location: 3 locations
Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for the Treatment of Multiple Myeloma in Ultra-Frail Patients
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
An Attenuated Schedule of the Dara-RVd Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone for Treatment of Relapsed or Recurrent Multiple Myeloma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Venetoclax, Tagraxofusp, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Asparaginase Erwinia Chrysanthemi with Chemotherapy for the Treatment of High-Risk Adults with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
KTE-X19 with Conditioning Chemotherapy for the Treatment of Patients with MRD Positive B-Cell Acute Lymphoblastic Leukemia Following Induction Therapy
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota